POS1498 COMORBIDITIES AND SAFETY EVENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multiorgan involvement. High activity may drive the development of comorbidities and safety events in SLE. Objectives To assess prevalence history at time Lupus Erythematosus Disease Activity Index (SLEDAI) assessment incidence newly diagnosed post-SLEDAI among prevalent cohort adult SLE patients ≥18 years old. Methods This was retrospective observational study using OM1 Registry data from January 2013 to February 2022 (OM1, Inc., Boston, MA). The index date defined as first observed or estimated SLEDAI score ≥12 months prior occurring after diagnosis. baseline period included all including date. follow-up for identifying incident available Incidence rates were stratified by activity. Results Among 10,837 patients, mean age 52 92% female. most common existing hypertension (44%), fibromyalgia (32%), anemia (29%), dyslipidemia thyroid (26%), obesity (25%), depression (22%), rheumatoid arthritis anxiety (19%), Sjögren’s syndrome (18%). History commonly any infection (11%), abnormal liver function tests, hepatitis, acute injury (ALI) (8%), elevated creatinine kidney (AKI) (6%), malignancy (5%). Most treated first-line therapy (glucocorticoids and/or antimalarials) during (89%). Use second-line (methotrexate, azathioprine, leflunomide) third-line (belimumab, anifrolumab, mycophenolate mofetil, mycophenolic acid, tacrolimus, cyclosporine, voclosporin, rituximab) therapies less (29% 30%, respectively). During follow-up, 36% had no activity, 28% mild 22% moderate 14% severe Greater associated higher hypertension, dyslipidemia, anxiety, disease, end-stage renal dialysis, chronic disease/cirrhosis, avascular necrosis, seizures epilepsy, syndrome. regardless (30.7 per 1000 person-years [PY]), ALI (20.3 PY), AKI (17.9 PY). Correlation between varied outcome. Conclusion Many occur more frequently association clear. SLE-related systemic inflammation, comorbidities, effects treatment (both positive negative) likely contribute patients’ risk profiles. Table 1. Rates Stratified Score Comorbidity Safety Event No N=3,919 Mild N=3,022 Moderate N=2,413 Severe N=1,483 Hypertension 38.0 38.7 42.7 43.3 Dyslipidemia 31.8 32.0 34.3 35.7 Anxiety 26.9 30.9 32.3 38.5 Thyroid 23.6 24.3 27.2 29.0 End-stage dialysis 3.2 3.6 5.3 Chronic 4.0 5.0 5.2 Avascular necrosis 2.5 2.9 3.4 4.4 Seizures epilepsy 6.3 7.1 8.4 7.2 7.8 8.2 12.7 Abnormal 16.3 22.4 25.4 19.2 14.4 20.9 20.3 18.0 Any 24.7 23 36.4 30.6 Major adverse cardiovascular 8.1 9.2 6.6 Venous thromboembolism 2.3 4.6 7.0 5.6 cutoffs: (SLEDAI=0), low (SLEDAI=1-5), (SLEDAI=6-10), (SLEDAI=11+) Acknowledgements authors would like thank OM1, Inc. providing statistical analysis this project. Financial support provided AbbVie. All access relevant participated drafting, review, approval publication. honoraria payments made authorship. Disclosure Interests Whitney Krueger Shareholder of: AbbVie, Employee Danielle Feger Alan Friedman Thao Doan Kristin D’Silva